Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MGMT | P16455 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978776 | 1.00 | MAPT (0.35) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL257010 | 0.89 | ALDH1A1 (0.38) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL3955746 | 0.85 | MGMT (0.44) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL628550 | 0.84 | ALDH1A1 (0.41) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL166184 | 0.80 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL14786602 | 0.80 | MAPT (0.38) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL31620150 | 0.79 | ALDH1A1 (0.36) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL9871854 | 0.78 | ALDH1A1 (0.39) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL10083725 | 0.77 | HTT (0.37) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL2459755 | 0.76 | KMT2A (0.41) | MAPTALDH1A1SMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674481-A2 | CD73 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250368677-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3787635-B1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025096494-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240124512-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4334295-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuoscience, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117597333-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 维吉尔神经科学股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| US-7501513-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7276506-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
| EP-1539760-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018473-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | MAPT 3265/4885ALDH1A1 3052/4885SMN1; SMN2 3400/4885 |
| US-20240124512-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | MAPT 1485/4885ALDH1A1 889/4885SMN1; SMN2 624/4885 |
| US-11807658-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | MAPT 1485/4885ALDH1A1 889/4885SMN1; SMN2 624/4885 |
| US-20250368677-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | MAPT 1485/4885ALDH1A1 889/4885SMN1; SMN2 624/4885 |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | MAPT 681/4885ALDH1A1 2654/4885SMN1; SMN2 472/4885 |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | MAPT 919/4885ALDH1A1 1733/4885SMN1; SMN2 1061/4885 |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | MAPT 642/4885ALDH1A1 2467/4885SMN1; SMN2 4120/4885 |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | TNF, TNFRSF1A, TLR4 | MAPT 2410/4885ALDH1A1 3134/4885SMN1; SMN2 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.